

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vrignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/898,885	07/03/2001	Raghavan Rajagopalan	MRD / 62	2179
26875 7	590 08/13/2003			
WOOD, HERRON & EVANS, LLP 2700 CAREW TOWER			EXAMINER	
441 VINE STR	REET		CEPERLEY, MARY	
CINCINNATI,	OH 45202		ART UNIT	PAPER NUMBER
			1641	
			DATE MAILED: 08/13/2003	5

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)			
Office Action Summary		09/898,885	RAJAGOPALAN ET AL.			
		Examiner	Art Unit			
		Mary (Molly) E. Ceperley	1641			
	The MAILING DATE of this communication app					
THE - Exterested after - If the - If NC - Failu - Any rearner - Status	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be within the statutory minimum of thirty (30) will apply and will expire SIX (6) MONTHS for cause the application to become ABANDO date of this communication, even if timely for	e timely filed days will be considered timely. om the mailing date of this communication.			
1)	Responsive to communication(s) filed on					
2a)⊠		s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) 40 and 41 is/are pending in the application.						
4a) Of the above claim(s) <u>41</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>40</u> is/are rejected.					
7)	7) Claim(s) is/are objected to.					
8)□	8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10)□ 1	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)□ 1	he proposed drawing correction filed on	is: a) ☐ approved b) ☐ disapp	roved by the Examiner.			
_	If approved, corrected drawings are required in rep					
12)☐ The oath or declaration is objected to by the Examiner.						
Priority u	nder 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority documents have been received.					
:	2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a)	a) The translation of the foreign language provisional application has been received.					
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(
2) D Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	4) Interview Summa 5) Notice of Informal 6) Other:	ry (PTO-413) Paper No(s) Patent Application (PTO-152)			
U.S. Patent and Trace PTO-326 (Rev.		on Summary	Part of Paper No. 15			

Application/Control Number: 09/898,885

Art Unit: 1641

1) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

2) Claim 40 is again rejected under 35 USC 102(b) as being anticipated by each of Pochinok et al, Ol'shevskaya et al, Clecak et al, and Leung et al for the reasons of record. Applicants' arguments filed May 21, 2003 have been fully considered but they are not persuasive.

In response to applicants' argument that "a compound in a solvent does not become a pharmaceutical formulation simply because it is dissolved in a solvent that applicants may use", a recitation of the intended use of the claimed invention must result in a <u>structural difference</u> between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is <u>capable of performing the intended use</u>, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

Applicants' argument regarding the enablement of the prior art references (Remarks, page 4, second and third paragraphs) is immaterial to the rejection at issue. The compositions of the prior art references are clearly enabled for their stated intended use. However, there is no requirement in the statue that the compositions of the prior art be enabled for the <u>same</u> use as the compositions of the instant invention, although both the claimed compositions and those of the prior art function as dyes. As stated in the paragraph directly *supra*, if the prior art structure is capable of performing the intended use, then it meets the claim. Additionally, the *Amgen Inc. v. Hoechst Marion Roussel, Inc.* decision cited by applicants is not pertinent to the rejection at issue. The *Amgen* case involved claimed and prior art compounds which both had the same stated utility unlike the claimed compositions of the instant application and those of the applied prior art.

With regard to applicants' argument that one skilled in the art would not be able to prepare a pharmaceutically acceptable formulation absent undue experimentation (Remarks, page 4, last

paragraphs), it is noted that Leung et al suggests a topical application of the disclosed dyes to living cells, i.e., "the dyes of the present invention are generally <u>non-toxic</u> to living cells" (col. 22, lines 17-18) and "the amount of fluorescent cyanine dye required for staining the cellular membranes of <u>live</u> mammalian cells, is preferably between 0.1 and 20 microM" (col. 21, lines 45-47). This disclosure is consistent with that of the instant specification wherein delivery of the composition may be "topical" (page 16, lines 1-2) and concentrations of the active ingredient are in the range of "1 microM to 10 mM" (page 15, lines 17-18) or "from 0.1 to 500mg/kg body weight" (page 16, lines 3-4).

3) THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

4) Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. (Molly) Ceperley whose telephone number is (703) 308-4239. The examiner can normally be reached from 8 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, can be reached at (703) 305-3399. The fax phone number for responses to be filed BEFORE final rejection is (703) 308-4556. The fax phone number for responses to be filed AFTER final rejection is (703) 305-3592.

Application/Control Number: 09/898,885

Art Unit: 1641

Questions which are <u>NOT RELATED TO THE EXAMINATION ON THE MERITS</u>, should be directed to <u>TC 1600 CUSTOMER SERVICE</u> at (703) 308-0198. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

August 08, 2003

Mary E. (Molly) Ceperley Primary Examiner Page 4

Art Unit 1641